Bevacizumab and Retinal Ischemia
Abstract
The unselective anti–vascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA) has been used for the treatment of diabetic retinopathy (DR), with early promising results.1Haritoglou C. Kook D. Neubauer A. et al.Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.Retina. 2006; 26: 999-1005Crossref PubMed Scopus (375) Google Scholar, 2Avery R.L. Pearlman...
Paper Details
Title
Bevacizumab and Retinal Ischemia
Published Date
Nov 1, 2007
Journal
Volume
114
Issue
11
Pages
2096 - 2096.e2
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History